{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044764","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.422550+00:00","generated_at":"2026-05-24T04:49:25.084270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction","bullets":["Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.","Cash, equivalents $108.5M at Dec 31, 2024; cash runway expected into H2 2026.","PBGENE-HBV Phase 1 low-dose cohort (N=3) dosed; well-tolerated with no grade ≥2 AE; 2 of 3 patients showed substantial HBsAg reduction.","Partner iECURE reported complete clinical response in first infant dosed for OTC deficiency; ECUR-506 generally well tolerated.","Appointed Cindy Atwell as Chief Development and Business Officer and Dr. Cassie Gorsuch as Chief Scientific Officer in Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044764","json":"https://secwatch.observer/filing/0000950170-25-044764.json","markdown":"https://secwatch.observer/filing/0000950170-25-044764.md","text":"https://secwatch.observer/filing/0000950170-25-044764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/0000950170-25-044764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/dtil-20250326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:49:25.084270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}